Hamilton Bennett | Sr. Director Vaccine Access and Partnerships

Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna

Hamilton Bennett (she/her) is the Senior Director of Vaccine Access and Partnerships at Moderna, a company pioneering messenger RNA (mRNA) therapeutics and vaccines. Hamilton maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. In this role, Hamilton led the mRNA-1273 COVID-19 vaccine development Program Team to the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Most recently, Hamilton launched mRNA Access to provide researchers access to Moderna’s early development engine to collaboratively advance novel vaccines targeting emerging and neglected infectious disease. Prior to Moderna, Hamilton led small molecule and monoclonal antibody pandemic preparedness programs at two Boston biotech companies. Hamilton holds a M.Sc from University of Washington in Environmental Health with a focus on Global Health, and a B.Sc from McGill University in Agricultural Chemistry and is pursuing an executive MBA from MIT.


Day 3 - November 30 @ 09:40

Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

  • Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
  • Are broad-spectrum (pan-variant) prophylactics a possible way forward?
  • When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
  • Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
  • Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
  • Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?
last published: 02/Jan/24 12:15 GMT

back to speakers